Recce Pharmaceuticals Provides Business Update - Seite 2

DFI Efficacy Achieved: Expansion of Phase I/II DFI Clinical Trial

Recce is actively pursuing an expansion of its clinical trial sites for its Phase I/II trial evaluating R327 in patients with DFIs, with notable sites identified and expected to come online during the present quarter, including one of the largest and most comprehensive regional health services in Australia based out of Victoria, and a world-class private hospital in Western Australia.

This strategic initiative aims to access a greater patient population, enhancing the diversity and depth of clinical data gathered. By forging collaborations with these esteemed institutions, the Company continues to demonstrate its commitment to advancing medical research and delivering innovative solutions that could potentially transform patient outcomes.

The Company is actively advancing its latest international expansion in Indonesia for a DFI clinical trial, moving steadily towards the initiation of a Phase III registrational trial scheduled to commence in Q3 2024.

R327 works and keeps on working with repeated use: tested in more than 300 Strains of Bacterial Pathogens – Effective Against All

The Company continues to work with leading experts dedicated to the discovery and development of innovative technologies, Linnaeus Bioscience, where they have tested R327 against more than 300 strains between the ESKAPE group of pathogens (198 Gram-negative and 111 Gram-positive bacteria strains). Chief Operations Officer of Linnaeus, Hannah Tsunemoto, Ph.D., led the experiments against these pathogens and commented, “R327 is effective against all strains tested at MICs.”

Gram-positive representatives			Gram-negative representatives
Bacteria	Strains		Bacteria	Strains
Enterococcus spp.	33		K. pneumoniae	38
S. aureus	65		A. baumannii	53
Enterobacter spp.	13		P. aeruginosa	63
			Salmonella	4
Total	198		E. coli	40
			Total	111

More than 95% of the strains tested were clinically isolated from a variety of sources, including but not limited to wounds, blood, urine, and sputum (phlegm).